• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 9Subject characteristics in randomized controlled clinical trials that examined harms with interventions for migraine prevention in children

Drugs References for RCTs*Age
# RCTs / Mean
[Min to Max]
% Females
# RCTs / Mean
[Min to Max]
Baseline Frequency of Migraine/Month
# RCTs / Mean
[Min to Max]
Duration of Migraine, Years
# RCTs / Mean
[Min to Max]
Obesity, BMI
# RCTs / Mean
[Min to Max]
Family History of Migraine, %
# RCTs / Mean
[Min to Max]
Topiramate81,82,86,874 / 13.4
[11.1 to 14.2]
4 / 60.4
[48.4 to 71.0]
2 / 4.7
[4.1 to 5.2]
02 / 23.3
[21.7 to 24.9]
0
Divalproex69,73,961 / 14.21 / 55.01 / 17.201 / 23.20
Propranolol8001 / 46.21 / 14.0001 / 13.0
Trazodone701 / 12.61 / 45.01 / 3.81 / 4.501 / 67.5
Clonidine71,721 / 11.02 / 41.4
[38.6 to 44.2]
1 / 3.5]001 / 90.7
Magnesium741 / 12.01 / 68.61 / 10.51 / 3.500
Total8 / 12.6
[11.0 to 14.2]
10 / 49.9
[38.6 to 71.0]
7 / 10.1
[3.5 to 17.2]
2 / 4.0
[3.5 to 4.5]
3 / 23.3
[21.7 to 24.9]
3 / 57.1
[13.0 to 67.5]

BMI = body mass index; RCT = randomized controlled trial

*

Includes multiple publications of RCTs.

Includes multiple publications of RCTs.

From: Results

Cover of Migraine in Children: Preventive Pharmacologic Treatments
Migraine in Children: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 108.
Shamliyan TA, Kane RL, Ramakrishnan R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.